Alterations in urokinase levels and impairment in fibrinolytic system in non insulin dependent diabetes mellitus (niddm)

K. Krekora, L. Iacoviello, D. De Lucia, C. Amore, G. Dooijewaard, A. Consoli, F. Capani, M. B. Donati

Research output: Contribution to journalArticle

Abstract

"Angela Valenti" Laboratory of Thrombosis Pharmacology. Istituto Mario Negri, Consorzio Mario Negri Sud, 66030 S. Maria Imbaro, 1 Institute of General Pathology and Oncology, II University ot Naples, Italy, 2 Gaubius Laboratory, TNO-PG, Leiden, The Netherlands and 3 Facolta di Medicina, Université di Chieti, Italy. NIDDM has been associated with an increased incidence of atherothrombotic complications. Abnormalities in the haemostatic system contribute at least in part to the development of atherothrombosis. In particular an increase in fibrinogen levels and a decrease in fibrinolytic potential, mainly due to tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1) alterations have been described. However, no informations are presently available on urokinase (UK) levels in NIDDM patients. To analyze the fibrinolytic system in NIDDM, UK activity (BIA = scuPA + tcuPA), UK antigen (ELISA = scuPA + tcuPA + uPA.Inh complex), fibrinogen, t-PA and PAI-1 were studied in 58 patients (22 women and 36 men; age 63±10) with NIDDM. In NIDDM patients there was no increase in UK both activity and antigen after venous stasis. However, the levels of UK activity (1.8±0.6 vs. 2.2±0.6 ng/ml p

Original languageEnglish
Pages (from-to)23
Number of pages1
JournalFibrinolysis
Volume10
Issue numberSUPPL. 3
Publication statusPublished - 1996

Fingerprint

Urokinase-Type Plasminogen Activator
Type 2 Diabetes Mellitus
Plasminogen Activator Inhibitor 1
Fibrinogen
Italy
Antigens
Plasminogen Activators
Tissue Plasminogen Activator
Hemostatics
Netherlands
Thrombosis
Enzyme-Linked Immunosorbent Assay
Pharmacology
Pathology
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Alterations in urokinase levels and impairment in fibrinolytic system in non insulin dependent diabetes mellitus (niddm). / Krekora, K.; Iacoviello, L.; De Lucia, D.; Amore, C.; Dooijewaard, G.; Consoli, A.; Capani, F.; Donati, M. B.

In: Fibrinolysis, Vol. 10, No. SUPPL. 3, 1996, p. 23.

Research output: Contribution to journalArticle

Krekora, K, Iacoviello, L, De Lucia, D, Amore, C, Dooijewaard, G, Consoli, A, Capani, F & Donati, MB 1996, 'Alterations in urokinase levels and impairment in fibrinolytic system in non insulin dependent diabetes mellitus (niddm)', Fibrinolysis, vol. 10, no. SUPPL. 3, pp. 23.
Krekora, K. ; Iacoviello, L. ; De Lucia, D. ; Amore, C. ; Dooijewaard, G. ; Consoli, A. ; Capani, F. ; Donati, M. B. / Alterations in urokinase levels and impairment in fibrinolytic system in non insulin dependent diabetes mellitus (niddm). In: Fibrinolysis. 1996 ; Vol. 10, No. SUPPL. 3. pp. 23.
@article{72cf748c73744451b7fc087d97d2254b,
title = "Alterations in urokinase levels and impairment in fibrinolytic system in non insulin dependent diabetes mellitus (niddm)",
abstract = "{"}Angela Valenti{"} Laboratory of Thrombosis Pharmacology. Istituto Mario Negri, Consorzio Mario Negri Sud, 66030 S. Maria Imbaro, 1 Institute of General Pathology and Oncology, II University ot Naples, Italy, 2 Gaubius Laboratory, TNO-PG, Leiden, The Netherlands and 3 Facolta di Medicina, Universit{\'e} di Chieti, Italy. NIDDM has been associated with an increased incidence of atherothrombotic complications. Abnormalities in the haemostatic system contribute at least in part to the development of atherothrombosis. In particular an increase in fibrinogen levels and a decrease in fibrinolytic potential, mainly due to tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1) alterations have been described. However, no informations are presently available on urokinase (UK) levels in NIDDM patients. To analyze the fibrinolytic system in NIDDM, UK activity (BIA = scuPA + tcuPA), UK antigen (ELISA = scuPA + tcuPA + uPA.Inh complex), fibrinogen, t-PA and PAI-1 were studied in 58 patients (22 women and 36 men; age 63±10) with NIDDM. In NIDDM patients there was no increase in UK both activity and antigen after venous stasis. However, the levels of UK activity (1.8±0.6 vs. 2.2±0.6 ng/ml p",
author = "K. Krekora and L. Iacoviello and {De Lucia}, D. and C. Amore and G. Dooijewaard and A. Consoli and F. Capani and Donati, {M. B.}",
year = "1996",
language = "English",
volume = "10",
pages = "23",
journal = "Fibrinolysis and Proteolysis",
issn = "1369-0191",
publisher = "Churchill Livingstone",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Alterations in urokinase levels and impairment in fibrinolytic system in non insulin dependent diabetes mellitus (niddm)

AU - Krekora, K.

AU - Iacoviello, L.

AU - De Lucia, D.

AU - Amore, C.

AU - Dooijewaard, G.

AU - Consoli, A.

AU - Capani, F.

AU - Donati, M. B.

PY - 1996

Y1 - 1996

N2 - "Angela Valenti" Laboratory of Thrombosis Pharmacology. Istituto Mario Negri, Consorzio Mario Negri Sud, 66030 S. Maria Imbaro, 1 Institute of General Pathology and Oncology, II University ot Naples, Italy, 2 Gaubius Laboratory, TNO-PG, Leiden, The Netherlands and 3 Facolta di Medicina, Université di Chieti, Italy. NIDDM has been associated with an increased incidence of atherothrombotic complications. Abnormalities in the haemostatic system contribute at least in part to the development of atherothrombosis. In particular an increase in fibrinogen levels and a decrease in fibrinolytic potential, mainly due to tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1) alterations have been described. However, no informations are presently available on urokinase (UK) levels in NIDDM patients. To analyze the fibrinolytic system in NIDDM, UK activity (BIA = scuPA + tcuPA), UK antigen (ELISA = scuPA + tcuPA + uPA.Inh complex), fibrinogen, t-PA and PAI-1 were studied in 58 patients (22 women and 36 men; age 63±10) with NIDDM. In NIDDM patients there was no increase in UK both activity and antigen after venous stasis. However, the levels of UK activity (1.8±0.6 vs. 2.2±0.6 ng/ml p

AB - "Angela Valenti" Laboratory of Thrombosis Pharmacology. Istituto Mario Negri, Consorzio Mario Negri Sud, 66030 S. Maria Imbaro, 1 Institute of General Pathology and Oncology, II University ot Naples, Italy, 2 Gaubius Laboratory, TNO-PG, Leiden, The Netherlands and 3 Facolta di Medicina, Université di Chieti, Italy. NIDDM has been associated with an increased incidence of atherothrombotic complications. Abnormalities in the haemostatic system contribute at least in part to the development of atherothrombosis. In particular an increase in fibrinogen levels and a decrease in fibrinolytic potential, mainly due to tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1) alterations have been described. However, no informations are presently available on urokinase (UK) levels in NIDDM patients. To analyze the fibrinolytic system in NIDDM, UK activity (BIA = scuPA + tcuPA), UK antigen (ELISA = scuPA + tcuPA + uPA.Inh complex), fibrinogen, t-PA and PAI-1 were studied in 58 patients (22 women and 36 men; age 63±10) with NIDDM. In NIDDM patients there was no increase in UK both activity and antigen after venous stasis. However, the levels of UK activity (1.8±0.6 vs. 2.2±0.6 ng/ml p

UR - http://www.scopus.com/inward/record.url?scp=33846674207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846674207&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 23

JO - Fibrinolysis and Proteolysis

JF - Fibrinolysis and Proteolysis

SN - 1369-0191

IS - SUPPL. 3

ER -